"Vaccine X"[ Journal] - Search Results

Year	Number of Results
2018	3
2019	39
2020	21
2021	47
2022	120
2023	169
2024	142

1

COVID-19 vaccine or booster uptake and hesitancy for children aged 6 months-5 years in the United States: A national descriptive study using the household pulse survey between March and May 2023.

Park C, Zabala PV. Park C, et al. Vaccine X. 2024 Nov 7;21:100582. doi: 10.1016/j.jvacx.2024.100582. eCollection 2024 Dec. Vaccine X. 2024. PMID: 39624679 Free PMC article.

2

Sex differences in COVID-19 vaccine confidence in people living with HIV in Canada.

Lu J, Vulesevic B, Burchell AN, Singer J, Needham J, Yang Y, Qian H, Chambers C, Samji H, Colmegna I, Del Canto S, Godin GH, Habanyama M, Hui SSC, Kroch A, Mandarino E, Margolese S, Martin C, Owino M, Lau E, Mohammadi T, Zhang W, Pelaez S, Kovacs C, Benko E, Cooper CL, Anis AH, Costiniuk CT; COVAXHIV Study Group. Lu J, et al. Vaccine X. 2024 Oct 5;21:100566. doi: 10.1016/j.jvacx.2024.100566. eCollection 2024 Dec. Vaccine X. 2024. PMID: 39582795 Free PMC article.

3

Association between vaccination and persistent COVID-19-related symptoms among patients with mild Omicron infection: A prospective cohort study.

Rover MM, Scolari FL, Trott G, da Silva MMD, de Souza D, da Rosa Minho Dos Santos R, De Carli Schardosim RF, de Souza Roldão E, Pozza Estivalete G, Rech GS, Mocellin D, de Souza JMB, Miozzo AP, Itaqui CR, da Silva GN, de Mesquita Neto J, Freitas HJM, Dos Santos CVP, da Silveira AS, D'Ávila CM, Soares CM, Vítor Gozzi J, Dos Santos IF, Carvalho SM, Irineu VM, Silvestre OM, do Carmo Marinho Borges K, de Menezes Neves PDM, Junior FAM, Schleder JC, Dos Santos TP, Lanna Figueiredo E, da Fonseca BAL, Zimmermann SL, Pompilho MA, Facchi LM, Gebara OCE, Marcolino MS, Antonio ACP, Schvartzman PR, Barreto BB, Robinson CC, Falavigna M, Nasi LA, Polanczyk CA, Biolo A, Rosa RG. Rover MM, et al. Vaccine X. 2024 Nov 4;21:100579. doi: 10.1016/j.jvacx.2024.100579. eCollection 2024 Dec. Vaccine X. 2024. PMID: 39582794 Free PMC article.

4

Lot quality assurance sampling for coverage evaluation of a new vaccine: A pilot study.

Hora R, Ray A, Longchar I, Rio GR, Mehra R, Koshal SS, Kumari A, Quadri SF, Kaur A, Roy AD. Hora R, et al. Vaccine X. 2024 Nov 1;21:100578. doi: 10.1016/j.jvacx.2024.100578. eCollection 2024 Dec. Vaccine X. 2024. PMID: 39559738 Free PMC article.

5

Social network characteristics of COVID-19 vaccination and preventive health behaviors: Cross-sectional findings from the US northeast during the early COVID-19 pandemic.

Khanna AS, Monnig MA, Clark SE, Monti PM. Khanna AS, et al. Vaccine X. 2024 Oct 28;21:100577. doi: 10.1016/j.jvacx.2024.100577. eCollection 2024 Dec. Vaccine X. 2024. PMID: 39555244 Free PMC article.

6

COVID-19 vaccine evidence monitoring assisted by artificial Intelligence: An emergency system implemented by the Public Health Agency of Canada to capture and describe the trajectory of evolving pandemic vaccine literature.

Hyun Lim S, Hersi M, Krishnan R, Montroy J, Rook B, Farrah K, Chung YE, Stevens A, Zafack J, Wong E, Forbes N, Killikelly A, Young K, Tunis M. Hyun Lim S, et al. Vaccine X. 2024 Oct 24;21:100575. doi: 10.1016/j.jvacx.2024.100575. eCollection 2024 Dec. Vaccine X. 2024. PMID: 39555243 Free PMC article.

7

Trust in the science behind COVID-19 vaccines as a driver of vaccine acceptance in the United States, 2021-2023.

White TM, Wyka K, Rabin K, El-Mohandes A. White TM, et al. Vaccine X. 2024 Oct 29;21:100576. doi: 10.1016/j.jvacx.2024.100576. eCollection 2024 Dec. Vaccine X. 2024. PMID: 39555242 Free PMC article.

8

Typhoid conjugate vaccine implementation in India: A review of supportive evidence.

Mogasale VV, Sinha A, John J, Hasan Farooqui H, Ray A, Chantler T, Mogasale V, Gopal Dhoubhadel B, John Edmunds W, Clark A, Abbas K. Mogasale VV, et al. Vaccine X. 2024 Oct 1;21:100568. doi: 10.1016/j.jvacx.2024.100568. eCollection 2024 Dec. Vaccine X. 2024. PMID: 39507102 Free PMC article. Review.

9

Pulmonary embolism after SARS-CoV-2 vaccination.

Zethelius B, Attelind S, Westman G, Ljung R, Sundström A. Zethelius B, et al. Vaccine X. 2024 Oct 15;21:100571. doi: 10.1016/j.jvacx.2024.100571. eCollection 2024 Dec. Vaccine X. 2024. PMID: 39474208 Free PMC article.

10

Association of the belief in conspiracy narratives with vaccination status and recommendation behaviours of German physicians.

Taubert F, Schmid P, Holford D, Verger P, Fasce A, Karlsson LC, Soveri A, Lewandowsky S, Betsch C. Taubert F, et al. Vaccine X. 2024 Oct 5;20:100560. doi: 10.1016/j.jvacx.2024.100560. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39444597 Free PMC article.

11

A literature review and evidence-based evaluation of the Dutch national immunisation schedule yield possibilities for improvements.

Pluijmaekers AJM, Steens A, Houweling H, Rots NY, Benschop KSM, van Binnendijk RS, Bodewes R, Brouwer JGM, Buisman A, Duizer E, van Els CACM, Hament JM, den Hartog G, Kaaijk P, Kerkhof K, King AJ, van der Klis FRM, Korthals Altes H, van der Maas NAT, van Meijeren DL, Middeldorp M, Rijnbende-Geraerts SD, Sanders EAM, Veldhuijzen IK, Vlaanderen E, Voordouw ACG, Vos ERA, de Wit J, Woudenberg T, van Vliet JA, de Melker HE. Pluijmaekers AJM, et al. Vaccine X. 2024 Sep 26;20:100556. doi: 10.1016/j.jvacx.2024.100556. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39444596 Free PMC article. Review.

12

Exploring the landscape of routine immunization in Nigeria: A scoping review of barriers and facilitators.

Mohammed Y, Reynolds HW, Waziri H, Attahiru A, Olowo-Okere A, Kamateeka M, Waziri NE, Garba AM, Corrêa GC, Garba R, Vollmer N, Nguku P. Mohammed Y, et al. Vaccine X. 2024 Sep 26;20:100563. doi: 10.1016/j.jvacx.2024.100563. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39430738 Free PMC article. Review.

13

Predictors of measles-rubella vaccination status in the Savannah Region, Ghana: A cross-sectional study among caregivers of children aged 18-59 months.

Adjei MR, Sarfo KA, Azornu CK, Kwarteng PG, Osei-Sarpong F, Baafi JV, Asamoah B, Kubio C, Grobusch MP, Ohene SA. Adjei MR, et al. Vaccine X. 2024 Sep 29;20:100567. doi: 10.1016/j.jvacx.2024.100567. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39411006 Free PMC article.

14

Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adults.

Bredholt G, Sævik M, Søyland H, Ueland T, Zhou F, Pathirana R, Madsen A, Vahokoski J, Lartey S, Halvorsen BE, Dahl TB, Trieu MC, Mohn KG, Brokstad KA, Aukrust P, Tøndel C, Langeland N, Blomberg B, Cox RJ; Bergen COVID-19 Research Group. Bredholt G, et al. Vaccine X. 2024 Sep 25;20:100564. doi: 10.1016/j.jvacx.2024.100564. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39403561 Free PMC article.

15

Time-course analysis of antibody and cytokine response after the third SARS-CoV-2 vaccine dose.

Kim HH, Lee HK, Hennighausen L, Furth PA, Sung H, Huh JW. Kim HH, et al. Vaccine X. 2024 Sep 24;20:100565. doi: 10.1016/j.jvacx.2024.100565. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39399820 Free PMC article.

16

Social networks and COVID-19 vaccination intention in Dutch middle-aged and older adults in 2020: Insights into individual, interpersonal, community, and societal determinants - The SaNAE study.

Steijvers LCJ, van Bilsen CJA, Wagner S, Stutterheim SE, Crutzen R, Ruiter RAC, Hoebe CJPA, Dukers-Muijrers NHTM. Steijvers LCJ, et al. Vaccine X. 2024 Sep 24;20:100562. doi: 10.1016/j.jvacx.2024.100562. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39399819 Free PMC article.

17

Persistence of hepatitis B surface antibody until 7 years of age following administration of hexavalent and pentavalent vaccines in children at 2, 4, 6, and 18 months.

Wanlapakorn N, Sarawanangkoor N, Srimuan D, Thatsanathorn T, Klinfueng S, Poovorawan Y. Wanlapakorn N, et al. Vaccine X. 2024 Sep 20;20:100561. doi: 10.1016/j.jvacx.2024.100561. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39385752 Free PMC article.

18

Caregiver acceptance of human papillomavirus vaccine for their female children in Chileka, Blantyre, Malawi.

Bwanali AN, Liundi P, Lubanga AF, Mpinganjira SL, Gadama LA. Bwanali AN, et al. Vaccine X. 2024 Sep 18;20:100557. doi: 10.1016/j.jvacx.2024.100557. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39381544 Free PMC article.

19

Impact of Bacille Calmette-Guérin vaccination on the therapeutic schedule of infantile epileptic spasms syndrome: A 25-year Japanese single-center survey.

Kobayashi H, Inoue H, Matsushige T, Hoshide M, Kohno F, Hidaka I, Hasegawa S. Kobayashi H, et al. Vaccine X. 2024 Sep 18;20:100558. doi: 10.1016/j.jvacx.2024.100558. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39381543 Free PMC article.

20

Enhanced production of recombinant coxsackievirus A16 using a serum-free HEK293A suspension culture system for bivalent enterovirus vaccine development.

Chen YA, Shen YS, Fang CY, Chan TT, Wu SR, Wang JR, Wu SC, Liu CC. Chen YA, et al. Vaccine X. 2024 Sep 19;20:100559. doi: 10.1016/j.jvacx.2024.100559. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39364390 Free PMC article.

21

Oral cholera vaccine coverage in Goma, Democratic Republic of the Congo, 2022, following 2019-2020 targeted preventative mass campaigns.

Briskin E, Bateyi Mustafa SH, Mahamba R, Kabunga D, Kubuya J, Porten K; Epicentre-MSF DRC cholera working group; Akilimali L, Okitayemba Welo P, Broban A. Briskin E, et al. Vaccine X. 2024 Sep 12;20:100555. doi: 10.1016/j.jvacx.2024.100555. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39315336 Free PMC article.

22

Characteristics of inpatient and outpatient respiratory syncytial virus mortality in Gavi-eligible countries.

Willemsen JE, Vernooij FS, Shaaban FL, Chikoti C, Bont LJ, Drylewicz J; RSV GOLD study group. Willemsen JE, et al. Vaccine X. 2024 Sep 13;20:100554. doi: 10.1016/j.jvacx.2024.100554. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39315335 Free PMC article.

23

Kinetics of humoral and cellular immune responses 5 months post-COVID-19 booster dose by immune response groups at the peak immunity phase: An observational historical cohort study using the Fukushima vaccination community survey.

Kobashi Y, Kawamura T, Shimazu Y, Kaneko Y, Nishikawa Y, Sugiyama A, Tani Y, Nakayama A, Yoshida M, Zho T, Yamamoto C, Saito H, Takita M, Wakui M, Kodama T, Tsubokura M. Kobashi Y, et al. Vaccine X. 2024 Sep 12;20:100553. doi: 10.1016/j.jvacx.2024.100553. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39309610 Free PMC article.

24

Vaccine optimization for highly pathogenic avian influenza: Assessment of antibody responses and protection for virus-like particle vaccines in chickens.

Ku CC, Lin CY, Yang CR, Yang YC, Chen PL, Lin YT, Wang PR, Lee MS, Liang SM, Hsiao PW. Ku CC, et al. Vaccine X. 2024 Sep 6;20:100552. doi: 10.1016/j.jvacx.2024.100552. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39309609 Free PMC article.

25

Clearance of anal and penile HPV 6, 11, 16, and 18 DNA and antibodies among adolescent men who have sex with men (HYPER): An observational cohort study.

Tian T, Fu L, Wang B, Zhou X, Lin YF, Gao Y, Li Y, Sun Y, Dai J, Zou H. Tian T, et al. Vaccine X. 2024 Sep 1;20:100551. doi: 10.1016/j.jvacx.2024.100551. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39290530 Free PMC article.

26

Queuing analysis for improving performance in bacterial vaccine quality control process.

Martha SA, Yunani A, Setiabudi W, Harsanto B. Martha SA, et al. Vaccine X. 2024 Aug 22;20:100550. doi: 10.1016/j.jvacx.2024.100550. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39263367 Free PMC article.

27

Human papilloma virus vaccination in the resource-limited settings of sub-Saharan Africa: Challenges and recommendations.

Murewanhema G, Moyo E, Dzobo M, Mandishora-Dube RS, Dzinamarira T. Murewanhema G, et al. Vaccine X. 2024 Aug 20;20:100549. doi: 10.1016/j.jvacx.2024.100549. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39263366 Free PMC article. Review.

28

Comparison of measles plaque reduction neutralization test (PRNT) and measles virus-specific IgG ELISA for assessment of immunogenicity of measles-mumps-rubella vaccination at 5-7 months of age and maternal measles antibodies.

Vittrup DM, Jensen A, Malon M, Zimakoff AC, Kiehn Sørensen J, Littell B, Simões EAF, Svensson J, Graff Stensballe L. Vittrup DM, et al. Vaccine X. 2024 Aug 16;20:100548. doi: 10.1016/j.jvacx.2024.100548. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39247133 Free PMC article.

29

Science-based exit from stringent countermeasures against COVID-19: Mortality prediction using immune landscape between 2021 and 2022 in Japan.

Kayano T, Sasanami M, Nishiura H. Kayano T, et al. Vaccine X. 2024 Aug 12;20:100547. doi: 10.1016/j.jvacx.2024.100547. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39238533 Free PMC article.

30

Safety pharmacology of human endogenous retrovirus-enveloped baculoviral DNA vaccines against SARS-CoV-2 in Sprague-Dawley rats and beagle dogs.

Park SJ, Seo JW, Han KH, Lee BS, Lee C, Kim BY, Ko KC, Kim YB. Park SJ, et al. Vaccine X. 2024 Aug 3;20:100545. doi: 10.1016/j.jvacx.2024.100545. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39221182 Free PMC article.

31

Assessment of the knowledge, attitude, and perception of the world's population towards monkeypox and its vaccines: A systematic review and descriptive analysis of cross-sectional studies.

Tanashat M, Altobaishat O, Sharaf A, Hossam El Din Moawad M, Al-Jafari M, Nashwan AJ. Tanashat M, et al. Vaccine X. 2024 Aug 2;20:100527. doi: 10.1016/j.jvacx.2024.100527. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39221181 Free PMC article. Review.

32

Influenza virus strains expressing SARS-CoV-2 receptor binding domain protein confer immunity in K18-hACE2 mice.

Rader NA, Lee KS, Loes AN, Miller-Stump OA, Cooper M, Wong TY, Boehm DT, Barbier M, Bevere JR, Heath Damron F. Rader NA, et al. Vaccine X. 2024 Aug 3;20:100543. doi: 10.1016/j.jvacx.2024.100543. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39221180 Free PMC article.

33

COVID-19 vaccines are effective at preventing symptomatic and severe infection among healthcare workers: A clinical review.

Galgut O, Ashford F, Deeks A, Ghataure A, Islam M, Sambhi T, Ker YW, Duncan CJA, de Silva TI, Hopkins S, Hall V, Klenerman P, Dunachie S, Richter A. Galgut O, et al. Vaccine X. 2024 Aug 5;20:100546. doi: 10.1016/j.jvacx.2024.100546. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39221179 Free PMC article. Review.

34

Safety and antibody responses of Omicron BA.4/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study.

Kanokudom S, Chansaenroj J, Suntronwong N, Wongsrisang L, Aeemjinda R, Vichaiwattana P, Thatsanathorn T, Chantima W, Pakchotanon P, Duangchinda T, Sudhinaraset N, Honsawek S, Poovorawan Y. Kanokudom S, et al. Vaccine X. 2024 Jul 28;20:100538. doi: 10.1016/j.jvacx.2024.100538. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39211731 Free PMC article.

35

Logistic and organizational barriers to herpes zoster vaccination in europe: A systematic review.

Sorrentino M, Belpiede A, Fiorilla C, Mercogliano M, Triassi M, Palladino R. Sorrentino M, et al. Vaccine X. 2024 Aug 3;20:100544. doi: 10.1016/j.jvacx.2024.100544. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39206078 Free PMC article. Review.

36

Comparison of anti-phospholipid antibody titers before and after SARS-CoV-2 mRNA vaccination in hospital staff.

Hisano M, Morisaki N, Sampei M, Obikane E, Yamaguchi K. Hisano M, et al. Vaccine X. 2024 Jul 30;20:100539. doi: 10.1016/j.jvacx.2024.100539. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39189026 Free PMC article.

37

Development of multidose thermotolerant formulations of a vector-based Covid-19 vaccine candidate, NDV-HXP-S in different product formats: Stability and preservative efficacy study.

Bzami A, Zhu C, Estrada M, White JA, Lal M. Bzami A, et al. Vaccine X. 2024 Jul 27;20:100535. doi: 10.1016/j.jvacx.2024.100535. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39189025 Free PMC article.

38

Assessing vaccine hesitancy and vaccine literacy among the European prison population and staff: A multicentre observational study.

Petri D, Fornili M, Vita E, Malanima MA, Yiasemi I, Mavrou J, Trattonikolas T, Stylianou I, Meroueh F, Murauer E, Mieuset A, Ranieri R, Cocco N, Busmachiu V, Barbirosh I, Tataru L, Doltu S, Mazzilli S, Tavoschi L, Baglietto L; RISE-Vac Consortium. Petri D, et al. Vaccine X. 2024 Jul 27;20:100537. doi: 10.1016/j.jvacx.2024.100537. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39189024 Free PMC article.

39

Determinants of costs of human papillomavirus vaccine delivery in six low- and middle-income countries.

Mvundura M, Slavkovsky R, Debellut F, Naddumba T, Pecenka C, Scott Lamontagne D; HPV vaccine cost of delivery study collaborators. Mvundura M, et al. Vaccine X. 2024 Jul 27;20:100534. doi: 10.1016/j.jvacx.2024.100534. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39185301 Free PMC article.

40

Association of maternal infection of SARS-CoV-2 and neonatal susceptibility: A retrospective cohort study.

Zhu XD, Peng YJ, Chen Y, Xue M, Zhang AJ, Peng Y, Mei R, Tian MR, Zhang L. Zhu XD, et al. Vaccine X. 2024 Jul 26;20:100536. doi: 10.1016/j.jvacx.2024.100536. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39176179 Free PMC article.

41

Contemporary provider perspectives on how to address HPV vaccine hesitancy in the US: A qualitative study.

Beavis AL, Krishnamoorthi MS, Adler S, Fleszar LG, Moran MB, Rositch AF. Beavis AL, et al. Vaccine X. 2024 Jul 24;20:100533. doi: 10.1016/j.jvacx.2024.100533. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39170855 Free PMC article.

42

Associations of mothers' decisional conflicts and satisfaction with governmental health promotion materials with their daughters' HPV vaccination uptake in China: A cross-sectional survey.

Lin Z, Chen S, Su L, Cao H, Chen H, Fang Y, Liang X, Chen J, Luo B, Wu C, Wang Z. Lin Z, et al. Vaccine X. 2024 Jul 20;19:100529. doi: 10.1016/j.jvacx.2024.100529. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39161948 Free PMC article.

43

Factors influencing parental COVID-19 vaccination willingness for children in Japan.

Ueta M, Cao A, Murakami M, Tomoi H, Gilmour S, Maruyama-Sakurai K, Takayama Y, Takebayashi Y, Hashizume M, Kumar RS, Kunishima H, Naito W, Yasutaka T, Kaneko S, Miyata H, Nomura S. Ueta M, et al. Vaccine X. 2024 Jul 18;19:100528. doi: 10.1016/j.jvacx.2024.100528. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39161947 Free PMC article.

44

Active offer of Tdap vaccination in a cohort of healthcare workers of Maternal and Neonatal Department: Data from a large hospital in Southern Italy.

Di Lorenzo A, Capodiferro L, Illuzzi M, Scaltrito C, Vimercati L, Moscara L, Tafuri S, Stefanizzi P. Di Lorenzo A, et al. Vaccine X. 2024 Jul 18;19:100530. doi: 10.1016/j.jvacx.2024.100530. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39157686 Free PMC article.

45

Knowledge of caregivers regarding pneumococcal diseases and pneumococcal conjugate vaccine (PCV): A cross sectional study at a district in India.

Majumder J, Ray A, Haldar P, Deb Roy A, Roy D, Chandra Mandal N, Mahapatra T. Majumder J, et al. Vaccine X. 2024 Jul 20;19:100532. doi: 10.1016/j.jvacx.2024.100532. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39157685 Free PMC article.

46

Effects of different HA and NA gene combinations on the growth characteristics of the H3N8 influenza candidate vaccine virus.

Liu L, Li Z, Liu J, Li X, Zhou J, Xiao N, Yang L, Wang D. Liu L, et al. Vaccine X. 2024 Jul 18;19:100531. doi: 10.1016/j.jvacx.2024.100531. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39157684 Free PMC article.

47

Post-introduction evaluation (PIE) of rotavirus vaccine in India.

Kumar P, Ray A, Kumari A, Kaur A, Hora R, Singh K, Mehra R, Koshal SS, Verma S, Quadri SF, Deb Roy A. Kumar P, et al. Vaccine X. 2024 Jul 17;19:100526. doi: 10.1016/j.jvacx.2024.100526. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39135678 Free PMC article.

48

Cost-effectiveness analysis of NVX-CoV2373 COVID-19 vaccination for elderly people in Japan.

Kato M, Ono T, Deguchi H, Ohmagari N, Igarashi A. Kato M, et al. Vaccine X. 2024 Jun 20;19:100514. doi: 10.1016/j.jvacx.2024.100514. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39108420 Free PMC article.

49

Strategies used to improve vaccine uptake among healthcare providers: A systematic review.

de Koning R, Gonzalez Utrilla M, Spanaus E, Moore M, Lomazzi M. de Koning R, et al. Vaccine X. 2024 Jul 2;19:100519. doi: 10.1016/j.jvacx.2024.100519. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39105135 Free PMC article. Review.

50

How stressful was the COVID-19 vaccination procedure? Comparison between mass vaccination centers and general practices.

Schrimpf A, Jentzsch A, Bleckwenn M, Geier AK. Schrimpf A, et al. Vaccine X. 2024 Jul 9;19:100524. doi: 10.1016/j.jvacx.2024.100524. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39105134 Free PMC article.

51

HTLV-1 vaccination Landscape: Current developments and challenges.

Letafati A, Bahari M, Salahi Ardekani O, Nayerain Jazi N, Nikzad A, Norouzi F, Mahdavi B, Aboofazeli A, Mozhgani SH. Letafati A, et al. Vaccine X. 2024 Jul 16;19:100525. doi: 10.1016/j.jvacx.2024.100525. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39105133 Free PMC article. Review.

52

Lipodystrophy following Covid-19 Vaccination: A case report.

Shakarami M, Sinaei F, Ghaderi Yazdi B, Ziaadini B. Shakarami M, et al. Vaccine X. 2024 Jun 22;19:100513. doi: 10.1016/j.jvacx.2024.100513. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39091362 Free PMC article.

53

Assessment of safety and adverse events following COVID-19 vaccination and their predictors in first 30 days among healthcare workers of a tertiary care teaching hospital in North India.

Bashar MA, Kamble B, Kumar S, Nandekar SV, Mathur SK. Bashar MA, et al. Vaccine X. 2024 Jul 5;19:100522. doi: 10.1016/j.jvacx.2024.100522. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39077369 Free PMC article.

54

Mental health symptom associations with COVID-19 testing and vaccination among urban American Indian and Alaska Native people.

Haskins C, Noonan C, MacLehose R, Buchwald D, Manson SM. Haskins C, et al. Vaccine X. 2024 Jul 4;19:100520. doi: 10.1016/j.jvacx.2024.100520. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39077368 Free PMC article.

55

Trust in health workers and patient-centeredness of care were strongest factors associated with vaccination for Kenyan children born between 2017-2022.

Moucheraud C, Ochieng E, Ogutu V, Sudhinaraset M, Szilagyi PG, Hoffman RM, Glenn B, Golub G, Njomo D. Moucheraud C, et al. Vaccine X. 2024 Jul 4;19:100523. doi: 10.1016/j.jvacx.2024.100523. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39070930 Free PMC article.

56

A cost benefit analysis of varicella vaccination in South Korea.

Lee YH, Choe YJ. Lee YH, et al. Vaccine X. 2024 Jul 4;19:100521. doi: 10.1016/j.jvacx.2024.100521. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39070929 Free PMC article.

57

Influenza virus circulation and vaccine effectiveness during June 2021-May 2023 in Thailand.

Prasert K, Praphasiri P, Nakphook S, Ditsungnoen D, Sapchookul P, Sornwong K, Naosri S, Akkapaiboon Okada P, Suntarattiwong P, Chotpitayasunondh T, Montgomery MP, Davis WW, Pittayawonganon C. Prasert K, et al. Vaccine X. 2024 Jun 28;19:100517. doi: 10.1016/j.jvacx.2024.100517. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39044732 Free PMC article.

58

Safety profile assessment of HPV4 and HPV9 vaccines through the passive surveillance system of the Veneto Region (Italy) between 2008 and 2022: A 15-year retrospective observational study.

Dalla Valle D, Benoni R, Soriolo N, Battistella C, Moretti F, Gonella LA, Tardivo S, Colpo S, Montresor S, Russo F, Tonon M, Da Re F, Moretti U, Zanoni G. Dalla Valle D, et al. Vaccine X. 2024 Jun 21;19:100511. doi: 10.1016/j.jvacx.2024.100511. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39040889 Free PMC article.

59

Effectiveness and duration of additional immune defense provided by SARS-CoV-2 infection before and after receiving the mRNA COVID-19 vaccine BNT162b2.

Shimada N, Sugawa S, Murakami S, Shinoda M, Ota S, Morikawa M, Takei H, Serizawa Y, Takahashi H, Toyama-Kousaka M, Matsuse H, Shinkai M. Shimada N, et al. Vaccine X. 2024 Jun 26;19:100518. doi: 10.1016/j.jvacx.2024.100518. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39040888 Free PMC article.

60

A phase 3, randomised, observer-blinded, placebo controlled-trial evaluating the safety and immunogenicity of investigational SARS-CoV-2 mRNA vaccine CVnCoV in adult healthcare workers in Mainz (Germany).

Kowalzik F, Teschner D, Mesquita M, Jensen C, Schreiner D, Kronfeld K, Tubic-Grozdanis M, Cheatham-Seitz D, Hettich F, Quintini G, Schoenborn-Kellenberger O, Codó P, von Eisenhart-Rothe P, Mann P, Oostvogels L, Gehring S. Kowalzik F, et al. Vaccine X. 2024 Jun 20;19:100512. doi: 10.1016/j.jvacx.2024.100512. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39040887 Free PMC article.

61

Adverse events of COVID-19 vaccination during 2021-2022 suppressed by breakfast consumption and favorable sleeping habit among Japanese university students.

Tetsuka N, Suzuki K, Suzuki K, Ishihara T, Miwa T, Tajirika S, Adachi M, Horita R, Fukao T, Yamamoto M. Tetsuka N, et al. Vaccine X. 2024 Jun 22;19:100516. doi: 10.1016/j.jvacx.2024.100516. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39040886 Free PMC article.

62

Exploring COVID-19 vaccine hesitancy among young adults in Australia. A qualitative study.

Sum Z, Sofija E, Sebar B. Sum Z, et al. Vaccine X. 2024 Jun 22;19:100515. doi: 10.1016/j.jvacx.2024.100515. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39040885 Free PMC article.

63

Why did I participate in an HIV vaccine study? Experiences of participation in the first phase II HIV vaccine trial in Mozambique: An ancillary study using a mixed-method approach.

Ubisse Capitine IP, Manhiça ÁM, Tembe Júnior P, Ramgi PM, Chicumbe S, Kroidl A, Fischer MR, De Schacht C. Ubisse Capitine IP, et al. Vaccine X. 2024 Jun 6;19:100510. doi: 10.1016/j.jvacx.2024.100510. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39021617 Free PMC article.

64

Comirnaty-induced cardiopulmonary distress and other symptoms of complement-mediated pseudo-anaphylaxis in a hyperimmune pig model: Causal role of anti-PEG antibodies.

Barta BA, Radovits T, Dobos AB, Tibor Kozma G, Mészáros T, Berényi P, Facskó R, Fülöp T, Merkely B, Szebeni J. Barta BA, et al. Vaccine X. 2024 May 23;19:100497. doi: 10.1016/j.jvacx.2024.100497. eCollection 2024 Aug. Vaccine X. 2024. PMID: 38933697 Free PMC article.

65

Impacts of COVID-19 vaccine boosters on clinical outcomes associated with the Omicron variant in China: A cross-sectional survey.

Feng H, Chen J, Sun J, Jiang Y. Feng H, et al. Vaccine X. 2024 Jun 6;19:100508. doi: 10.1016/j.jvacx.2024.100508. eCollection 2024 Aug. Vaccine X. 2024. PMID: 38903607 Free PMC article.

66

Vaccine delivery systems and administration routes: Advanced biotechnological techniques to improve the immunization efficacy.

Bouazzaoui A, Abdellatif AAH. Bouazzaoui A, et al. Vaccine X. 2024 May 24;19:100500. doi: 10.1016/j.jvacx.2024.100500. eCollection 2024 Aug. Vaccine X. 2024. PMID: 38873639 Free PMC article. Review.

67

Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials.

Whitworth HS, Mounier-Jack S, Choi EM, Gallagher KE, Howard N, Kelly H, Mbwanji G, Kreimer AR, Basu P, Barnabas R, Drolet M, Brisson M, Watson-Jones D. Whitworth HS, et al. Vaccine X. 2024 Apr 16;19:100486. doi: 10.1016/j.jvacx.2024.100486. eCollection 2024 Aug. Vaccine X. 2024. PMID: 38873638 Free PMC article. Review.

68

A qualitative assessment of influenza vaccine uptake among children in Kenya.

Liku N, Mburu C, Lafond KE, Ebama M, Athman M, Swaleh S, Jewa I, Ngware E, Njenga V, Kiptoo E, Munyao C, Miano C, Anyango E, Thuo S, Matini W, Mirieri H, Otieno N, Athman M, Chanzera P, Awadh Z, Muthoni M, Kingori P, Kariuki Njenga M, Emukule GO, Osoro E, Tabu C, Dawa J. Liku N, et al. Vaccine X. 2024 May 27;19:100507. doi: 10.1016/j.jvacx.2024.100507. eCollection 2024 Aug. Vaccine X. 2024. PMID: 38873637 Free PMC article.

69

Evaluation of the immunoprotective power of a multiple antigenic peptide against Aah II toxin of Androctonus australis hector scorpion.

Benazzouz SM, Benlouahmia N, Bouhadida K, Benlamara M, Arezki N, Sadeddine OEK, Issad M, Attal N, Mansouri K, Derrar F, Djidjik R. Benazzouz SM, et al. Vaccine X. 2024 May 25;19:100503. doi: 10.1016/j.jvacx.2024.100503. eCollection 2024 Aug. Vaccine X. 2024. PMID: 38868522 Free PMC article.

70

How the African vaccine manufacturing accelerator can assist in strengthening Africa's response to global health challenges.

Omojuyigbe JO, Ade-Adekunle OA, Atobatele IR, Adekunle FO. Omojuyigbe JO, et al. Vaccine X. 2024 May 21;19:100499. doi: 10.1016/j.jvacx.2024.100499. eCollection 2024 Aug. Vaccine X. 2024. PMID: 38841419 Free PMC article. No abstract available.

71

The association of COVID-19 vaccination and menstrual health: A period-tracking app-based cohort study.

Ramaiyer M, El Sabeh M, Zhu J, Shea A, Segev D, Yenokyan G, Borahay MA. Ramaiyer M, et al. Vaccine X. 2024 May 18;19:100501. doi: 10.1016/j.jvacx.2024.100501. eCollection 2024 Aug. Vaccine X. 2024. PMID: 38832342 Free PMC article.

72

Digitizing tools for post introduction evaluation of rotavirus vaccine introduction in India.

Kumar P, Kaur A, Ray A, Singh K, Verma S, Hora R, Koshal SS, Kumari A, Mehra R, Quadri SF, Roy AD. Kumar P, et al. Vaccine X. 2024 May 23;19:100502. doi: 10.1016/j.jvacx.2024.100502. eCollection 2024 Aug. Vaccine X. 2024. PMID: 38827494 Free PMC article.

73

Vaccine hesitancy in adolescents regarding COVID-19 vaccination: A literature review.

Dhamayanti M, Andriyani R, Moenardi S, Karina PP. Dhamayanti M, et al. Vaccine X. 2024 Mar 19;18:100477. doi: 10.1016/j.jvacx.2024.100477. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38881780 Free PMC article. Review.

74

Investigation of the vaccine potential of an in silico designed FepA peptide vaccine against Shigella flexneri in mice model.

Ali MR, Mahmud S, Faruque MO, Hossain MI, Hossain MA, Kibria KMK. Ali MR, et al. Vaccine X. 2024 May 8;18:100493. doi: 10.1016/j.jvacx.2024.100493. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38812954 Free PMC article.

75

SARS-CoV-2 vaccination in Canadian blood donors: Insight into donor representativeness of the general population.

O'Brien SF, Goldman M, Ehsani-Moghaddam B, Fan W, Osmond L, Pambrun C, Drews SJ. O'Brien SF, et al. Vaccine X. 2024 May 12;18:100498. doi: 10.1016/j.jvacx.2024.100498. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38800670 Free PMC article.

76

Area and individual level analyses of demographic and socio-economic disparities in COVID-19 vaccination uptake in Belgium.

Hubin P, Van den Borre L, Braeye T, Cavillot L, Billuart M, Stouten V, Nasiadka L, Vermeiren E, Van Evercooren I, Devleesschauwer B, Catteau L, van Loenhout JAF. Hubin P, et al. Vaccine X. 2024 May 3;18:100496. doi: 10.1016/j.jvacx.2024.100496. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38779406 Free PMC article.

77

Detection of measles vaccine virus and measles-specific immunoglobulin M in children vaccinated against measles-mumps-rubella during measles outbreak.

Seo E, Chang YJ, Woo Chung J, Chung YS, Yeon Park S. Seo E, et al. Vaccine X. 2024 Apr 24;18:100491. doi: 10.1016/j.jvacx.2024.100491. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38746062 Free PMC article.

78

Presenting clinical symptoms of post-COVID-19 breakthrough infection: Predictors of mortality in a Middle Eastern population.

Albtoosh AS, Farah R, Al Oweidat K, Hussein OM, Obeid AA, Hamila HM, Radwan MNM, Ahmad RF, Masadeh HM, Hammad AI, Musleh AM, Fakhoury AA, Disi FM, Joudah YYS, Obeidat N, Mason KP. Albtoosh AS, et al. Vaccine X. 2024 May 4;18:100495. doi: 10.1016/j.jvacx.2024.100495. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38746061 Free PMC article.

79

Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults.

Ferguson M, Murray A, Pliamm L, Rombo L, Sanmartin Berglund J, David MP, De Schrevel N, Maschino F, Kotb S, Olivier A, Hulstrøm V. Ferguson M, et al. Vaccine X. 2024 Apr 27;18:100494. doi: 10.1016/j.jvacx.2024.100494. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38746060 Free PMC article.

80

Case-finding for HPV vaccination eligibility within a dental office with concurrent development of a dialogue tool.

Cable CE, Watson KE, Tsuyuki RT. Cable CE, et al. Vaccine X. 2024 Apr 23;18:100492. doi: 10.1016/j.jvacx.2024.100492. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38737622 Free PMC article.

81

Antibody responses to SARS-CoV-2 spike protein in a cohort of renal transplant recipients following two-dose primary immunization - A Caribbean country's perspective.

Roberts L, Alexander CM, Monteil M, Manjunath M, Mohammed E, Wilson V, Wilson S. Roberts L, et al. Vaccine X. 2024 Apr 20;18:100487. doi: 10.1016/j.jvacx.2024.100487. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38707481 Free PMC article.

82

Reduction of adverse reactions and correlation between post-vaccination fever and specific antibody response across successive SARS-CoV-2 mRNA vaccinations.

Tani N, Ikematsu H, Watanabe H, Goto T, Yanagihara Y, Kurata Y, Harada Y, Horiuchi T, Akashi K, Shimono N, Chong Y. Tani N, et al. Vaccine X. 2024 Apr 19;18:100489. doi: 10.1016/j.jvacx.2024.100489. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38699157 Free PMC article.

83

"I try to take all the time needed, even if i do not have it!": Knowledge, attitudes, practices of perinatal care providers in canada about vaccination.

Pringle W, Greyson D, Graham JE, Dubé È, Mitchell H, Russell ML, MacDonald SE, Bettinger JA. Pringle W, et al. Vaccine X. 2024 Apr 19;18:100490. doi: 10.1016/j.jvacx.2024.100490. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38699156 Free PMC article.

84

COVID-19 vaccine hesitancy prevalence in Mexico: A systematic review and metanalysis.

Ramonfaur D, Limaye RJ, Hinojosa-González DE, Barrera FJ, Rodríguez-Gómez GP, Castillo-Salgado C. Ramonfaur D, et al. Vaccine X. 2024 Apr 21;18:100488. doi: 10.1016/j.jvacx.2024.100488. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38699155 Free PMC article. Review.

85

Landscape review of active vaccine safety surveillance activities for COVID-19 vaccines globally.

ShamaeiZadeh PA, Jaimes CV, Knoll MD, Espié E, Chandler RE. ShamaeiZadeh PA, et al. Vaccine X. 2024 Apr 10;18:100485. doi: 10.1016/j.jvacx.2024.100485. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38655548 Free PMC article.

86

Changes in vaccination practices among infants after the introduction of DTaP-IPV/Hib combination vaccines.

Kim HJ, Park S, Jeong NY, Choi NK. Kim HJ, et al. Vaccine X. 2024 Apr 9;18:100484. doi: 10.1016/j.jvacx.2024.100484. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38655547 Free PMC article.

87

Vaccination coverage during pregnancy and factors associated with refusal of recommended vaccinations: An Italian cross sectional study.

Seravalli V, Romualdi I, Ammar O, De Blasi C, Boccalini S, Bechini A, Di Tommaso M. Seravalli V, et al. Vaccine X. 2024 Apr 8;18:100483. doi: 10.1016/j.jvacx.2024.100483. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38623567 Free PMC article.

88

Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: A case study of Nigeria.

Sun Y, Keskinocak P, Steimle LN, Kovacs SD, Wassilak SG. Sun Y, et al. Vaccine X. 2024 Mar 16;18:100476. doi: 10.1016/j.jvacx.2024.100476. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38617838 Free PMC article.

89

An ecological analysis of socio-economic determinants associated with paediatric vaccination coverage in the Campania Region: A population-based study, years 2003-2017.

Mercogliano M, Valdecantos RL, Fevola G, Sorrentino M, Buonocore G, Triassi M, Palladino R. Mercogliano M, et al. Vaccine X. 2024 Mar 28;18:100482. doi: 10.1016/j.jvacx.2024.100482. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38585381 Free PMC article.

90

Global disparities in COVID-19 vaccine booster dose (VBD) acceptance and hesitancy: An updated narrative review.

Roy DN, Ferdiousi N, Mohabbot Hossen M, Islam E, Shah Azam M. Roy DN, et al. Vaccine X. 2024 Mar 23;18:100480. doi: 10.1016/j.jvacx.2024.100480. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38585380 Free PMC article. Review.

91

Factors associated with childhood non-vaccination against COVID-19 in Canada: A national survey analysis.

Guan D, Dave S, Ebrahim M, Laroche JA. Guan D, et al. Vaccine X. 2024 Mar 20;18:100478. doi: 10.1016/j.jvacx.2024.100478. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38572339 Free PMC article.

92

COVID-19 vaccine acceptance and associated determinants in Addis Ketema Sub-city, Addis Ababa, Ethiopia: A community-based study.

Kassie Getahun G, Sefefe H, Shitemaw T, Yirsaw Wubete B. Kassie Getahun G, et al. Vaccine X. 2024 Mar 20;18:100481. doi: 10.1016/j.jvacx.2024.100481. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38559754 Free PMC article.

93

Enablers and barriers to rotavirus vaccine coverage in Assam, India- A qualitative study.

Mehra R, Ray A, Das S, Biman Kusum Chowdhury, Singh Koshal S, Hora R, Kumari A, Kaur A, Quadri SF, Deb Roy A. Mehra R, et al. Vaccine X. 2024 Mar 19;18:100479. doi: 10.1016/j.jvacx.2024.100479. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38559753 Free PMC article.

94

Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand.

Chawansuntati K, Sakkhachornphop S, Hongjaisee S, Freeouf S, Sripan P, Nusartsang N, Chaiwarith R, Sudjaritruk T, Supparatpinyo K, Wipasa J. Chawansuntati K, et al. Vaccine X. 2024 Mar 16;18:100475. doi: 10.1016/j.jvacx.2024.100475. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38549951 Free PMC article.

95

Association of vaccination status and severity of SARS-CoV-2 infections in hospitalized patients.

Guerrero D, Baker T, Corn M, Keup S, Nickell A, Cao L. Guerrero D, et al. Vaccine X. 2024 Mar 13;18:100473. doi: 10.1016/j.jvacx.2024.100473. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38545562 Free PMC article.

96

A conceptual framework to model social determinants of COVID-19 vaccination uptake among underserved homeless populations.

Haidar S, Roederer T, Allaire C, Mollo B, Vincent C, Bonmarin I, Mosnier M, Richard E, Vandentorren S. Haidar S, et al. Vaccine X. 2024 Mar 14;18:100472. doi: 10.1016/j.jvacx.2024.100472. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38523621 Free PMC article.

97

Efficient and scalable clarification of Orf virus from HEK suspension for vaccine development.

Pagallies F, Labisch JJ, Wronska M, Pflanz K, Amann R. Pagallies F, et al. Vaccine X. 2024 Mar 13;18:100474. doi: 10.1016/j.jvacx.2024.100474. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38523620 Free PMC article.

98

Barriers to the assessment and recommendation of HPV vaccination among healthcare providers in Texas.

Chido-Amajuoyi OG, Osaghae I, Onyeaka HK, Shete S. Chido-Amajuoyi OG, et al. Vaccine X. 2024 Mar 13;18:100471. doi: 10.1016/j.jvacx.2024.100471. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38523619 Free PMC article.

99

Defining and reporting adverse events of special interest in comparative maternal vaccine studies: a systematic review.

Davies HG, Thorley EV, Al-Bahadili R, Sutton N, Burt J, Hookham L, Karampatsas K, Lambach P, Muñoz F, Cutland CL, Omer S, Le Doare K. Davies HG, et al. Vaccine X. 2024 Feb 23;18:100464. doi: 10.1016/j.jvacx.2024.100464. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38495929 Free PMC article. Review.

100

Using freeze-preventive cold boxes in rural Nepal: A study of equipment performance, acceptability, system fit, and cost.

Kumar S, Lennon P, Uranw S, Fielding T, Mvundura M, Drolet A, Diesburg S, Ray A, Dahal S, Lal B, Little J, Routray S. Kumar S, et al. Vaccine X. 2024 Feb 28;18:100467. doi: 10.1016/j.jvacx.2024.100467. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38463659 Free PMC article.

101

Personal rights over public Health: Anti-vaccine rhetoric in the Texas Legislature.

Matthews KRW, Lakshmanan R, Kalakuntla N, Tallapragada N. Matthews KRW, et al. Vaccine X. 2024 Feb 28;18:100468. doi: 10.1016/j.jvacx.2024.100468. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38450107 Free PMC article.

102

Using machine learning algorithms to predict COVID-19 vaccine uptake: A year after the introduction of COVID-19 vaccines in Ghana.

Dodoo CC, Hanson-Yamoah E, Adedia D, Erzuah I, Yamoah P, Brobbey F, Cobbold C, Mensah J. Dodoo CC, et al. Vaccine X. 2024 Feb 27;18:100466. doi: 10.1016/j.jvacx.2024.100466. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38444651 Free PMC article.

103

Individual and community-level determinants of pentavalent vaccination dropouts among under-five children in the sub-Saharan African countries: A multilevel analysis of the recent demographic and health survey.

Ferede Zegeye A, Kassa Mekonnen C, Kindie H, Shetie Workneh B, Bihonegn Asmamaw D, Tarik Tamir T. Ferede Zegeye A, et al. Vaccine X. 2024 Feb 22;17:100465. doi: 10.1016/j.jvacx.2024.100465. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38435980 Free PMC article.

104

Determinants of vaccination decisions and lived experiences of Ghanaians with the COVID-19 pandemic; a qualitative study.

Aggrey-Bluwey L, Abekah-Nkrumah G. Aggrey-Bluwey L, et al. Vaccine X. 2024 Feb 20;17:100463. doi: 10.1016/j.jvacx.2024.100463. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38425414 Free PMC article.

105

The cost of human papillomavirus vaccination delivery at the administrative and health facility levels in the Philippines.

Aldaba JG, Llave CL, Uy MEV, Tejano KP, Aquino MRC, Antonio P Catalig M, Sy ADR, Valverde HA, Mooney J, Slavkovsky R. Aldaba JG, et al. Vaccine X. 2024 Feb 18;17:100459. doi: 10.1016/j.jvacx.2024.100459. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38420134 Free PMC article.

106

Association between vaccination beliefs and COVID-19 vaccine uptake in a longitudinal panel survey of adults in the United States, 2021-2022.

Kranzler EC, Luchman JN, Margolis KA, Ihongbe TO, Kim JC, Denison B, Vuong V, Hoffman B, Dahlen H, Yu K, Dupervil D, Hoffman L. Kranzler EC, et al. Vaccine X. 2024 Feb 8;17:100458. doi: 10.1016/j.jvacx.2024.100458. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38405368 Free PMC article.

107

A stress-free and easy-to-use system to expose pigs to aerosols.

Jores J, Ruggli N, Scalisi N, Jang J, Torres-Puig S. Jores J, et al. Vaccine X. 2024 Feb 11;17:100457. doi: 10.1016/j.jvacx.2024.100457. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38390347 Free PMC article. No abstract available.

108

Human papillomavirus (HPV) vaccination program in Sri Lanka: Ongoing costs and operational context of a routinized program.

Debellut F, Gamage D, Kumar S, Wickramasinghe S, Ruwanpathirana T, Kariyawasam M, Perera CS, Ginige S, Cooray N, Pecenka C, Slavkovsky R, Scott LaMontagne D, Mvundura M. Debellut F, et al. Vaccine X. 2024 Feb 8;17:100456. doi: 10.1016/j.jvacx.2024.100456. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38379668 Free PMC article.

109

Reported effectiveness of COVID-19 monovalent booster vaccines and hybrid immunity against mild and severe Omicron disease in adults: A systematic review and meta-regression analysis.

Nealon J, Mefsin YM, McMenamin ME, Ainslie KEC, Cowling BJ. Nealon J, et al. Vaccine X. 2024 Feb 2;17:100451. doi: 10.1016/j.jvacx.2024.100451. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38379667 Free PMC article.

110

Attitudes and practices to adult vaccination among physicians before and after COVID-19 pandemic in the United Arab Emirates.

Barqawi HJ, Samara KA, Haddad ES, Bakkour LM, Amawi FB. Barqawi HJ, et al. Vaccine X. 2024 Feb 1;17:100455. doi: 10.1016/j.jvacx.2024.100455. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38356876 Free PMC article.

111

Compatible co-administration of BioThrax® vaccine and ciprofloxacin-Results of a randomized open-label drug-vaccine interaction trial.

Cassie D, Longstreth J, Hopkins R, Hunter-Stitt E, Drobic B, Bellani M. Cassie D, et al. Vaccine X. 2024 Jan 7;17:100431. doi: 10.1016/j.jvacx.2024.100431. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38352727 Free PMC article.

112

Parental gender influences their intention to HPV vaccinate their children, and the association between HPV and COVID-19 vaccination intentions.

Oka E, Ueda Y, Yagi A, Ito Y, Hosokawa Y, Tabuchi T, Kimura T. Oka E, et al. Vaccine X. 2024 Jan 20;17:100441. doi: 10.1016/j.jvacx.2024.100441. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38352726 Free PMC article.

113

National launch of human papillomavirus (HPV) immunization program in Poland, 2023.

Michalek IM, Koczkodaj P, Didkowska J. Michalek IM, et al. Vaccine X. 2024 Feb 1;17:100436. doi: 10.1016/j.jvacx.2024.100436. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38352725 Free PMC article.

114

Outlining recent updates on influenza therapeutics and vaccines: A comprehensive review.

Malik S, Asghar M, Waheed Y. Malik S, et al. Vaccine X. 2024 Jan 30;17:100452. doi: 10.1016/j.jvacx.2024.100452. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38328274 Free PMC article. Review.

115

Booster doses of an inactivated F genotype mumps vaccine enhance immunogenicity in mice.

Yeon Kim S, Lee TY, Hwang YH, Kim D, Kim YJ, Won H. Yeon Kim S, et al. Vaccine X. 2024 Jan 13;17:100437. doi: 10.1016/j.jvacx.2024.100437. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38317857 Free PMC article.

116

BpOmpW antigen administered with CAF01 adjuvant stimulates comparable T cell responses to Sigma adjuvant system.

Tomás-Cortázar J, Quinn C, Corcoran N, Blanco A, Christensen D, McClean S. Tomás-Cortázar J, et al. Vaccine X. 2024 Jan 13;17:100438. doi: 10.1016/j.jvacx.2024.100438. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38303776 Free PMC article.

117

IFN-α armed gE elicits superior immunogenicity compared to unmodified antigens and flagellin armed gE in mice.

Zhang J, Peng S, Xu F, Qiao Y, Ye X, Guan Y, Zhao X, Wang Y, Shao Z, Zhu T, Si W. Zhang J, et al. Vaccine X. 2024 Jan 6;17:100432. doi: 10.1016/j.jvacx.2024.100432. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38299205 Free PMC article.

118

Social determinants of low uptake of childhood vaccination in high-risk squatter settlements in Karachi, Pakistan - A step towards addressing vaccine inequity in urban slums.

Habib SS, Zaidi S, Riaz A, Tahir HN, Mazhar LA, Memon Z. Habib SS, et al. Vaccine X. 2023 Dec 30;17:100427. doi: 10.1016/j.jvacx.2023.100427. eCollection 2024 Mar. Vaccine X. 2023. PMID: 38299204 Free PMC article.

119

Characteristics and determinants of seasonal influenza vaccination in Manitoba, Canada: A population-wide record-linkage study.

Okoli GN, Righolt CH, Zhang G, Alessi-Severini S, Van Caeseele P, Fan Kuo I, Mahmud SM. Okoli GN, et al. Vaccine X. 2024 Jan 9;17:100435. doi: 10.1016/j.jvacx.2024.100435. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38299203 Free PMC article.

120

Overview of childhood vaccination coverage in Brazil and the impact of the COVID-19 pandemic: Is our children's health at risk? A review of pre-COVID-19 periods and during the COVID-19 pandemic.

Paula Martins J, Almeida Alatzatianos G, Mendes Camargo T, Augusto Lima Marson F. Paula Martins J, et al. Vaccine X. 2024 Jan 9;17:100430. doi: 10.1016/j.jvacx.2024.100430. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38299202 Free PMC article.

121

Patterns of basic pneumococcal conjugated vaccine coverage in Ethiopia from 2015 to 2018; further analysis of Ethiopian DHS (2016-2019).

Gamachu M, Mussa I, Deressa A, Tolera M, Birhanu A, Getachew T, Negash A, Jibro U, Abdurahman D, Motuma A, Mohammed F, Balis B, Demissie Regassa L. Gamachu M, et al. Vaccine X. 2024 Jan 6;17:100428. doi: 10.1016/j.jvacx.2024.100428. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38299201 Free PMC article. Review.

122

Effectiveness of the severe acute respiratory syndrome coronavirus 2 Omicron BA.5 bivalent vaccine on symptoms in healthcare workers with BA.5 infection.

Hirotsu Y, Takatori M, Mochizuki H, Omata M. Hirotsu Y, et al. Vaccine X. 2024 Jan 6;17:100433. doi: 10.1016/j.jvacx.2024.100433. eCollection 2024 Mar. Vaccine X. 2024. PMID: 38299200 Free PMC article.

123

In-depth reasons for the high proportion of zero-dose children in underserved populations of Ethiopia: Results from a qualitative study.

Biks GA, Shiferie F, Tsegaye DA, Asefa W, Alemayehu L, Wondie T, Seboka G, Hayes A, RalphOpara U, Zelalem M, Belete K, Donofrio J, Gebremedhin S. Biks GA, et al. Vaccine X. 2024 Feb 1;16:100454. doi: 10.1016/j.jvacx.2024.100454. eCollection 2024 Jan. Vaccine X. 2024. PMID: 38327767 Free PMC article.

124

Erratum to "Risk of cardiac arrhythmia and cardiac arrest after primary and booster COVID-19 vaccination in England: A self-controlled case series analysis" [Vaccine: X 15 (2023) 100418].

Stowe J, Whitaker HJ, Andrews NJ, Miller E. Stowe J, et al. Vaccine X. 2024 Jan 31;16:100449. doi: 10.1016/j.jvacx.2024.100449. eCollection 2024 Jan. Vaccine X. 2024. PMID: 38322609 Free PMC article.

125

Vaccine hesitancy for the COVID-19 vaccine booster dose among nursing home staff fully vaccinated with the primary vaccination course in Belgium.

Digregorio M, Van Ngoc P, Delogne S, Meyers E, Deschepper E, Dardenne N, Duysburgh E, De Rop L, De Burghgraeve T, Coen A, De Clercq N, De Sutter A, Verbakel JY, Cools P, Heytens S, Buret L, Scholtes B. Digregorio M, et al. Vaccine X. 2024 Jan 30;16:100453. doi: 10.1016/j.jvacx.2024.100453. eCollection 2024 Jan. Vaccine X. 2024. PMID: 38361529 Free PMC article.

126

Researching childhood vaccine hesitancy in the wake of COVID-19.

Anderson A, Douglass T, Hobson-West P. Anderson A, et al. Vaccine X. 2024 Jan 26;16:100450. doi: 10.1016/j.jvacx.2024.100450. eCollection 2024 Jan. Vaccine X. 2024. PMID: 38318231 Free PMC article.

127

SARS-CoV-2 vaccines in China could reduce COVID-19-related respiratory syndromes and deaths: A retrospective cohort study.

Yao W, Chen Y, Huang Q, Luo W, Chen Y, Xie C. Yao W, et al. Vaccine X. 2024 Jan 24;16:100448. doi: 10.1016/j.jvacx.2024.100448. eCollection 2024 Jan. Vaccine X. 2024. PMID: 38322611 Free PMC article.

128

Development of an RBD-Fc fusion vaccine for COVID-19.

Sun Y, Li Q, Luo Y, Zhu H, Xu F, Lu H, Yao P, Wang Z, Zhao W, Zhou Z. Sun Y, et al. Vaccine X. 2024 Jan 21;16:100444. doi: 10.1016/j.jvacx.2024.100444. eCollection 2024 Jan. Vaccine X. 2024. PMID: 38327768 Free PMC article.

129

Deciphering deaths associated with severe serious adverse events following SARS-CoV-2 vaccination: A retrospective cohort study.

Ha J, Song MC, Park S, Kang H, Kyung T, Kim N, Kim DK, Bae K, Lee KJ, Lee E, Hwang BS, Youn J, Seok JM, Park K. Ha J, et al. Vaccine X. 2024 Jan 20;16:100446. doi: 10.1016/j.jvacx.2024.100446. eCollection 2024 Jan. Vaccine X. 2024. PMID: 38318232 Free PMC article. No abstract available.

130

Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United States.

Layton JB, Peetluk L, Wong HL, Jiao Y, Djibo DA, Bui C, Lloyd PC, Gruber JF, Miller M, Ogilvie RP, Deng J, Parambi R, Song J, Weatherby LB, Lo AC, Matuska K, Wernecke M, Clarke TC, Cho S, Bell EJ, Seeger JD, Yang GW, Illei D, Forshee RA, Anderson SA, McMahill-Walraven CN, Chillarige Y, Amend KL, Anthony MS, Shoaibi A. Layton JB, et al. Vaccine X. 2024 Jan 20;16:100447. doi: 10.1016/j.jvacx.2024.100447. eCollection 2024 Jan. Vaccine X. 2024. PMID: 38318230 Free PMC article.

131

Humoral immune response after SARS-CoV-2 vaccination in cladribine-treated multiple sclerosis patients.

Mimpen M, Kreiter D, Kempkens T, Knippenberg S, Hupperts R, Gerlach O. Mimpen M, et al. Vaccine X. 2024 Jan 20;16:100445. doi: 10.1016/j.jvacx.2024.100445. eCollection 2024 Jan. Vaccine X. 2024. PMID: 38304878 Free PMC article.

132

Immunogenicity studies of recombinant RBD SARS-CoV-2 as a COVID-19 vaccine candidate produced in Escherichia coli.

Safitri IA, Sugijo Y, Puspasari F, Masduki FF, Ihsanawati, Giri-Rachman EA, Artarini AA, Tan MI, Natalia D. Safitri IA, et al. Vaccine X. 2024 Jan 20;16:100443. doi: 10.1016/j.jvacx.2024.100443. eCollection 2024 Jan. Vaccine X. 2024. PMID: 38304876 Free PMC article.

133

Maternal worry of children contracting COVID-19 predicts vaccine uptake in young children in Vermont.

Keene K, Balasubramanian A, Potter A, Cioffredi LA. Keene K, et al. Vaccine X. 2024 Jan 19;16:100442. doi: 10.1016/j.jvacx.2024.100442. eCollection 2024 Jan. Vaccine X. 2024. PMID: 38318233 Free PMC article.

134

Young adults' intention to encourage COVID-19 vaccination among their grandparents: A nationwide cross-sectional survey of college students in China.

Guo Z, Li X, Bian J, Zhang W, Lu Z, Sun Y, Gao Y, Fu L, Zou H. Guo Z, et al. Vaccine X. 2024 Jan 17;16:100439. doi: 10.1016/j.jvacx.2024.100439. eCollection 2024 Jan. Vaccine X. 2024. PMID: 38283624 Free PMC article.

135

Virus-like particles (VLPs): A promising platform for combating against Newcastle disease virus.

Taghizadeh MS, Niazi A, Afsharifar A. Taghizadeh MS, et al. Vaccine X. 2024 Jan 14;16:100440. doi: 10.1016/j.jvacx.2024.100440. eCollection 2024 Jan. Vaccine X. 2024. PMID: 38283623 Free PMC article. Review.

136

The impact of strategies for increasing vaccination coverage in children: A community clinical trial.

Fonseca Almeida Souza J, Philipe Rodrigues da Silva T, Aparecida Ferreira Latchim S, Wilson Rodrigues Vieira E, Francisca Martins E, Geralda Araújo D, de Castro da Silva B, Eliane Nobre Ribeiro E, Penido Matozinhos F. Fonseca Almeida Souza J, et al. Vaccine X. 2024 Jan 9;16:100429. doi: 10.1016/j.jvacx.2024.100429. eCollection 2024 Jan. Vaccine X. 2024. PMID: 38322610 Free PMC article.

137

Mpox knowledge and vaccination hesitancy among healthcare workers in Beijing, China: A cross-sectional survey.

Yang Y, Zhang W, Han B, Meng H, Wang J, Wu K, Fu L, Wang B, Jiang X, Li Q, Xu Z, Zhang Y, Qi X, Zou H. Yang Y, et al. Vaccine X. 2024 Jan 9;16:100434. doi: 10.1016/j.jvacx.2024.100434. eCollection 2024 Jan. Vaccine X. 2024. PMID: 38304877 Free PMC article.

138

E-mail as a way of communication during the ACWY meningococcal vaccination campaign in adolescents and young adults in the Region of Murcia.

Zornoza Moreno M, Isabel Tornel Minarro F, Jesus Perez Martin J. Zornoza Moreno M, et al. Vaccine X. 2023 Dec 15;16:100426. doi: 10.1016/j.jvacx.2023.100426. eCollection 2024 Jan. Vaccine X. 2023. PMID: 38205135 Free PMC article.

139

Evaluation of luciferase and prefusion-stabilized F protein from respiratory syncytial virus mRNA/LNPs in pre-clinical models using jet delivery compared to needle and syringe.

Meyer BK, Nahas D, An M, Danziger A, Smith J, Patel M, Lin SA, Gleason A, Cox K, Capen R, Howe J, Bett A. Meyer BK, et al. Vaccine X. 2023 Dec 9;16:100420. doi: 10.1016/j.jvacx.2023.100420. eCollection 2024 Jan. Vaccine X. 2023. PMID: 38192619 Free PMC article.

140

Delays in Hepatitis A vaccination in people with HIV in Houston, Texas between 2010 and 2018.

Ciocca ET, Staggers KA, Carey J, Opekun AR, Hollinger FB, Keitel WA, Atmar RL, El Sahly HM, Whitaker JA. Ciocca ET, et al. Vaccine X. 2023 Dec 14;16:100422. doi: 10.1016/j.jvacx.2023.100422. eCollection 2024 Jan. Vaccine X. 2023. PMID: 38192618 Free PMC article.

141

Vicarious experiences of long COVID: A protection motivation theory analysis for vaccination intentions.

Eitze S, Sprengholz P, Korn L, Shamsrizi P, Felgendreff L, Betsch C. Eitze S, et al. Vaccine X. 2023 Dec 7;16:100417. doi: 10.1016/j.jvacx.2023.100417. eCollection 2024 Jan. Vaccine X. 2023. PMID: 38192617 Free PMC article.

142

Adherence to the three-component Hepatitis B virus vaccination protocol among healthcare workers in hepatitis B virus endemic settings in Ghana.

Vivian Efua SD, Delali Adwoa W, Adiza Atoko M. Vivian Efua SD, et al. Vaccine X. 2023 Dec 10;16:100421. doi: 10.1016/j.jvacx.2023.100421. eCollection 2024 Jan. Vaccine X. 2023. PMID: 38145015 Free PMC article.

143

Nationwide safety surveillance of COVID-19 mRNA vaccines following primary series and first booster vaccination in Singapore.

Dorajoo SR, Tan HX, Teo CHD, Neo JW, Koon YL, Ng JJA, Tham MY, Foo PQB, Peck LF, Ang PS, Lim TA, Poh WWJ, Toh SLD, Chan CL, Douglas I, Soh BLS. Dorajoo SR, et al. Vaccine X. 2023 Dec 2;15:100419. doi: 10.1016/j.jvacx.2023.100419. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38130887 Free PMC article.

144

Association of COVID-19 information media, providers, and content with vaccine uptake among Tokyo residents.

Noguchi N, Yokoi R, Masu T, Watanabe M, Itoh S, Yumoto S. Noguchi N, et al. Vaccine X. 2023 Nov 19;15:100411. doi: 10.1016/j.jvacx.2023.100411. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38161990 Free PMC article.

145

COVID-19 vaccination and infection among people with self-reported chronic health conditions and disabilities vs. people without medical risk factors in a survey sample from Oslo.

Dimka J. Dimka J. Vaccine X. 2023 Nov 17;15:100409. doi: 10.1016/j.jvacx.2023.100409. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38161989 Free PMC article.

146

Validating pertussis data measures using electronic medical record data in Ontario, Canada 1986-2016.

McBurney SH, Kwong JC, Brown KA, Rudzicz F, Chen B, Candido E, Crowcroft NS. McBurney SH, et al. Vaccine X. 2023 Nov 21;15:100408. doi: 10.1016/j.jvacx.2023.100408. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38161988 Free PMC article.

147

Factors associated with COVID-19 vaccination among healthcare workers in an Algerian University Teaching Hospital: A cross-sectional study.

Dali-Ali A, Beneddine I, Midoun N, Oukebdane A. Dali-Ali A, et al. Vaccine X. 2023 Nov 22;15:100413. doi: 10.1016/j.jvacx.2023.100413. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38161987 Free PMC article.

148

Unraveling the association between vaccine attitude, vaccine conspiracies and self-reported side effects following COVID-19 vaccination among nurses and physicians in Jordan.

Sallam M, Abbasi H, Obeidat RJ, Badayneh R, Alkhashman F, Obeidat A, Oudeh D, Uqba Z, Mahafzah A. Sallam M, et al. Vaccine X. 2023 Nov 8;15:100405. doi: 10.1016/j.jvacx.2023.100405. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38161986 Free PMC article.

149

Antibody responses after BNT162b2 vaccination in Japanese geriatric intermediate care facilities.

Suita A, Ohfuji S, Kasamatsu A, Kondo K, Nakata H, Kita T, Deguchi A, Fujimoto M, Iba K, Sakamoto H, Iwasaka K, Sakamoto N, Sakamoto H, Yodoi Y, Kido Y, Nakagama Y, Konishi A, Mukai E, Matsumoto K, Matsuura T, Kase T, Kakeya H, Fukushima W, Hirota Y. Suita A, et al. Vaccine X. 2023 Nov 22;15:100412. doi: 10.1016/j.jvacx.2023.100412. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38161985 Free PMC article.

150

Impact of herpes zoster and post-herpetic neuralgia on health-related quality of life in Miyun District of Beijing, China: An EQ-5D survey.

Zhao D, Suo L, Lu L, Pan J, Peng X, Wang Y, Pang X. Zhao D, et al. Vaccine X. 2023 Nov 29;15:100415. doi: 10.1016/j.jvacx.2023.100415. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38124774 Free PMC article.

151

Hybrid immunity from SARS-CoV-2 infection and mRNA BNT162b2 vaccine among Thai school-aged children.

Saraban K, Suntarattiwong P, Chantasrisawad N, Boonsathorn S, Kosalaraksa P, Phongsamart W, Tangsathapornpong A, Jaruampornpan P, Srisarang S, Puthanakit T; KIDSVAX study team. Saraban K, et al. Vaccine X. 2023 Nov 24;15:100414. doi: 10.1016/j.jvacx.2023.100414. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38090644 Free PMC article.

152

Risk of cardiac arrhythmia and cardiac arrest after primary and booster COVID-19 vaccination in England: A self-controlled case series analysis.

Stowe J, Whitaker HJ, Andrews NJ, FMedSci EM. Stowe J, et al. Vaccine X. 2023 Dec 1;15:100418. doi: 10.1016/j.jvacx.2023.100418. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38090643 Free PMC article.

153

Distinctions between survivors and non-survivors with SARS-CoV-2 vaccine-induced thrombotic thrombocytopenia: A systematic review and meta-analysis.

Castro-Varela A, Garza Salas AK, Barrios-Ruiz A, Ambriz Morales E, Abascal-Lanzagorta P, Reyes-Chavez MF, Cárdenas-Rodríguez IT, Solorzano-Lopez EJ, Sánchez-Pizarro C, Fernando de Los Ríos Arce L, Vazquez-Garza E, Jerjes-Sanchez C. Castro-Varela A, et al. Vaccine X. 2023 Nov 18;15:100407. doi: 10.1016/j.jvacx.2023.100407. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38075434 Free PMC article.

154

Impact of implemented vaccination strategies on vaccine uptake and attitude of final year pharmacy students toward COVID-19 vaccines in Gezira State, Sudan.

Wedaa A, Elmustafa M, Babiker HA, Ahmed R. Wedaa A, et al. Vaccine X. 2023 Nov 28;15:100416. doi: 10.1016/j.jvacx.2023.100416. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38075433 Free PMC article.

155

Long-term immunity induced by SPBN GASGAS in orally vaccinated dogs is non-inferior to inactivated rabies vaccines.

Vos A, Kasemsuwan S, Leelahapongsathon K, Bobe K, Perez-Bravo D, Kliemt J, Phawaphutayanchi P, Aiyara N, Freuling CM, Müller T. Vos A, et al. Vaccine X. 2023 Nov 21;15:100410. doi: 10.1016/j.jvacx.2023.100410. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38075432 Free PMC article.

156

Influenza immunization of healthcare personnel in the post-COVID-19 pandemic era: Still a lot to do!

Ledda C, Motta G, Rapisarda V, Maltezou HC. Ledda C, et al. Vaccine X. 2023 Nov 2;15:100402. doi: 10.1016/j.jvacx.2023.100402. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38058792 Free PMC article.

157

COVID-19 vaccination in urban American Indian and Alaska Native children: Parental characteristics, beliefs and attitudes associated with vaccine acceptance.

Collier AF, Schaefer KR, Uddin A, Noonan C, Dillard DA, Son-Stone L, Manson SM, Buchwald D, MacLehose R; CONCERTS Collaborative. Collier AF, et al. Vaccine X. 2023 Nov 14;15:100406. doi: 10.1016/j.jvacx.2023.100406. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38058791 Free PMC article.

158

Effectiveness of COVID-19 vaccines in Ecuador: A test-negative design.

Pérez-Tasigchana F, Valcárcel-Pérez I, Arias-Quispe M, Astudillo L, Bruno A, Herrera G M, Armas R, de Mora D, Pinos J, Olmedo A, Salas R, Jimbo-Sotomayor R, Chiluisa C, Acosta P, Sánchez X, Whittembury A. Pérez-Tasigchana F, et al. Vaccine X. 2023 Nov 8;15:100404. doi: 10.1016/j.jvacx.2023.100404. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38033879 Free PMC article.

159

Crosslinked chitosan microparticles as a safe and efficient DNA carrier for intranasal vaccination against cutaneous leishmaniasis.

Costa Souza BLS, Pinto EF, Bezerra IPS, Gomes DCO, Martinez AMB, Ré MI, de Matos Guedes HL, Rossi-Bergmann B. Costa Souza BLS, et al. Vaccine X. 2023 Nov 3;15:100403. doi: 10.1016/j.jvacx.2023.100403. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38026045 Free PMC article.

160

Importance of adjuvant selection in tuberculosis vaccine development: Exploring basic mechanisms and clinical implications.

Gyu Choi H, Woong Kwon K, Jae Shin S. Gyu Choi H, et al. Vaccine X. 2023 Oct 29;15:100400. doi: 10.1016/j.jvacx.2023.100400. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37965276 Free PMC article. Review.

161

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18-55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial.

Ansarifar A, Farahani RH, Rahjerdi AK, Ahi M, Sheidaei A, Gohari K, Rahimi Z, Gholami F, Basiri P, Moradi M, Jahangiri A, Naderi K, Ghasemi S, Khatami P, Honari M, Khodaverdloo S, Shooshtari M, Azin HM, Moradi S, Shafaghi B, Allahyari H, Monazah A, Poor AK, Bakhshande H, Taghva Z, Nia MK, Dodaran MS, Foroughizadeh M. Ansarifar A, et al. Vaccine X. 2023 Oct 27;15:100401. doi: 10.1016/j.jvacx.2023.100401. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37941802 Free PMC article.

162

Detachable-dissolvable-microneedle as a potent subunit vaccine delivery device that requires no cold-chain.

Phoka T, Thanuthanakhun N, Visitchanakun P, Dueanphen N, Wanichwecharungruang N, Leelahavanichkul A, Palaga T, Ruxrungtham K, Wanichwecharungruang S. Phoka T, et al. Vaccine X. 2023 Oct 16;15:100398. doi: 10.1016/j.jvacx.2023.100398. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37920235 Free PMC article.

163

Influenza vaccination in Western Australian children: Exploring the health benefits and cost savings of increased vaccine coverage in children.

Blyth CC, Fathima P, Pavlos R, Jacoby P, Pavy O, Geelhoed E, Richmond PC, Effler PV, Moore HC. Blyth CC, et al. Vaccine X. 2023 Oct 18;15:100399. doi: 10.1016/j.jvacx.2023.100399. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37908895 Free PMC article.

164

Weaker SARS-CoV-2 vaccine responses in nonalcoholic fatty liver disease with advanced liver fibrosis.

Hakimian D, Amer J, Jammal A, Shafrir A, Milgrom Y, Masarowah M, Hazou W, Ishay Y, Imam A, Francis A, Khalaileh A, Safadi R. Hakimian D, et al. Vaccine X. 2023 Oct 12;15:100359. doi: 10.1016/j.jvacx.2023.100359. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37885772 Free PMC article.

165

Efficacy and safety of the recombinant zoster vaccine: A systematic review and meta-analysis.

Zeevaert R, Thiry N, Maertens de Noordhout C, Roberfroid D. Zeevaert R, et al. Vaccine X. 2023 Oct 14;15:100397. doi: 10.1016/j.jvacx.2023.100397. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37867572 Free PMC article. Review.

166

A cross-sectional study on the reasons for vaccine hesitancy in children under seven years of age in Isfahan, Iran.

Farajzadeh N, Hosseini H, Keshvari M, Maracy MR. Farajzadeh N, et al. Vaccine X. 2023 Oct 11;15:100396. doi: 10.1016/j.jvacx.2023.100396. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37867571 Free PMC article.

167

Administration of an excessive dosage of covid-19 pfizer vaccine in an infant: Case report of clinical and immune responses.

E Silva JM, Guimarães JB, Abu Jamra SR, Mirante BS, Capato CF, de Melo Jorge DM, da Fonseca BAL. E Silva JM, et al. Vaccine X. 2023 Oct 4;15:100395. doi: 10.1016/j.jvacx.2023.100395. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37841655 Free PMC article.

168

Analysis of global routine immunisation coverage shows disruption and stagnation during the first two-years of the COVID-19 pandemic with tentative recovery in 2022.

Evans B, Keiser O, Kaiser L, Jombart T. Evans B, et al. Vaccine X. 2023 Sep 6;15:100383. doi: 10.1016/j.jvacx.2023.100383. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37841654 Free PMC article.

169

An online RCT on behavioural expectations effects of COVID-19 certification policies in England.

Mills F, Carter H, Benny L, Barnard M, Symons C. Mills F, et al. Vaccine X. 2023 Sep 20;15:100389. doi: 10.1016/j.jvacx.2023.100389. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37829554 Free PMC article.

170

Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan.

Sonoyama T, Kamitani A, Shibata RY, Seki NM, Omoto S, Igarashi K, Ariyasu M. Sonoyama T, et al. Vaccine X. 2023 Sep 18;15:100390. doi: 10.1016/j.jvacx.2023.100390. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37822891 Free PMC article.

171

Immunization of children with inflammatory bowel disease against SARS-CoV-19 infection: A prospective single centre cohort study.

Dohos D, Karoliny A, Gombos E, Rimanóczy É, Müller KE. Dohos D, et al. Vaccine X. 2023 Aug 19;15:100374. doi: 10.1016/j.jvacx.2023.100374. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37822890 Free PMC article.

172

Estimation of cutoff score for the 7C of vaccination readiness scale.

Machida M, Takamiya T, Odagiri Y, Fukushima N, Kikuchi H, Inoue S. Machida M, et al. Vaccine X. 2023 Sep 26;15:100394. doi: 10.1016/j.jvacx.2023.100394. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37808267 Free PMC article.

173

Prices of paediatric vaccines in European vaccination programmes.

Salo H, Sakalauskaitè M, Lévy-Bruhl D, Lindstrand A, Valentiner-Branth P, Wichmann O, Puumalainen T. Salo H, et al. Vaccine X. 2023 Sep 20;15:100392. doi: 10.1016/j.jvacx.2023.100392. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37779660 Free PMC article.

174

Health workers vaccination: Experience and lessons learned from Costa Rica.

Morice A, Abarca-Gómez L, Arroba R, Luisa Avila-Agüero M, Salas-Peraza D, Shendale S, Desai S. Morice A, et al. Vaccine X. 2023 Aug 24;15:100376. doi: 10.1016/j.jvacx.2023.100376. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37779659 Free PMC article.

175

The relationship between vaccine acceptance and COVID-19 mortality in Europe: A Cross-Country analysis of public opinion and Epidemiological data.

Brnic S, Buric B, Marcec R, Likic R. Brnic S, et al. Vaccine X. 2023 Sep 19;15:100391. doi: 10.1016/j.jvacx.2023.100391. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37772201 Free PMC article.

176

Vaccination against COVID-19 and socioeconomic inequalities: A cross-sectional study in Ecuador.

Torres EC, Moreno M, Rivadeneira MF. Torres EC, et al. Vaccine X. 2023 Sep 20;15:100393. doi: 10.1016/j.jvacx.2023.100393. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37767539 Free PMC article.

177

Short-term safety of inactivated SARS-Cov-2 vaccines in Chinese patients with central nervous system inflammatory demyelinating diseases.

Zhao D, Zhang W, Ma X, Zhao R, Yao L, Lu J, Yan X, Bai M, Zhang G, Li H, Guo J. Zhao D, et al. Vaccine X. 2023 Sep 21;15:100388. doi: 10.1016/j.jvacx.2023.100388. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37767538 Free PMC article.

178

Pregnant women's attitudes and behaviours towards antenatal vaccination against Influenza and COVID-19 in the Liverpool City Region, United Kingdom: Cross-sectional survey.

Kilada S, French N, Perkins E, Hungerford D. Kilada S, et al. Vaccine X. 2023 Sep 16;15:100387. doi: 10.1016/j.jvacx.2023.100387. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37753114 Free PMC article.

179

Using new cold chain technologies to extend the vaccine cold chain in India: Equipment performance, acceptability, systems fit, and costs.

Kumar S, Mvundura M, Ray A, Haldar P, Lennon P, Muller N, Deb Roy A, Rewaria S. Kumar S, et al. Vaccine X. 2023 Sep 9;15:100385. doi: 10.1016/j.jvacx.2023.100385. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37736536 Free PMC article.

180

Production of recombinant lumpy skin disease virus A27L and L1R proteins for application in diagnostics and vaccine development.

Ntombela N, Matsiela M, Zuma S, Hiralal S, Naicker L, Mokoena N, Khoza T. Ntombela N, et al. Vaccine X. 2023 Sep 7;15:100384. doi: 10.1016/j.jvacx.2023.100384. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37736535 Free PMC article.

181

Longitudinal long COVID symptoms in Japanese patients after COVID-19 vaccinations.

Nakagawara K, Morita A, Namkoong H, Terai H, Chubachi S, Asakura T, Tanaka H, Ito F, Matsuyama E, Kaji M, Saito A, Takaoka H, Okada M, Sunata K, Watase M, Yagi K, Ohgino K, Miyata J, Kamata H, Kawada I, Kobayashi K, Hirano T, Inoue T, Kagyo J, Shiomi T, Otsuka K, Miyao N, Odani T, Baba R, Arai D, Nakachi I, Ueda S, Funatsu Y, Koh H, Ishioka K, Takahashi S, Nakamura M, Sato T, Hasegawa N, Kitagawa Y, Kanai T, Ishii M, Fukunaga K. Nakagawara K, et al. Vaccine X. 2023 Sep 1;15:100381. doi: 10.1016/j.jvacx.2023.100381. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37731516 Free PMC article.

182

The leptospiral OmpA-like protein (Loa22) is a surface-exposed antigen that elicits bactericidal antibody against heterologous Leptospira.

Schuler EJA, Patel DT, Marconi RT. Schuler EJA, et al. Vaccine X. 2023 Sep 1;15:100382. doi: 10.1016/j.jvacx.2023.100382. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37727366 Free PMC article.

183

Assessing the potential impact of COVID-19 booster doses and oral antivirals: A mathematical modelling study of selected middle-income countries in the Indo-Pacific.

Bilgin GM, Lokuge K, Munira SL, Glass K. Bilgin GM, et al. Vaccine X. 2023 Sep 9;15:100386. doi: 10.1016/j.jvacx.2023.100386. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37727365 Free PMC article.

184

Maternal vaccination against RSV can substantially reduce childhood mortality in low-income and middle-income countries: A mathematical modeling study.

Willemsen JE, Borghans JAM, Bont LJ, Drylewicz J. Willemsen JE, et al. Vaccine X. 2023 Sep 1;15:100379. doi: 10.1016/j.jvacx.2023.100379. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37711264 Free PMC article.

185

Factors associated with COVID-19 vaccination in Belize.

Rios-Zertuche D, Daga G, Iorillo F, Aguilar Rivera AM, Diaz-Musa M, Largaespada Beer N, López Boo F, Sabido J. Rios-Zertuche D, et al. Vaccine X. 2023 Sep 1;15:100380. doi: 10.1016/j.jvacx.2023.100380. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37693845 Free PMC article.

186

Randomized controlled field trial to assess the efficacy of an intranasal Moraxella bovis cytotoxin vaccine against naturally occurring infectious bovine keratoconjunctivitis.

Angelos JA, Agulto RL, Mandzyuk B, Chigerwe M. Angelos JA, et al. Vaccine X. 2023 Sep 1;15:100378. doi: 10.1016/j.jvacx.2023.100378. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37693844 Free PMC article.

187

Factors influencing neutralizing antibody response to the original SARS-CoV-2 virus and the Omicron variant in a high vaccination coverage country, a population-based study.

Hormazábal J, Nuñez-Franz L, Rubilar P, Apablaza M, Vial C, Cortés LJ, González N, Vial P, Said M, González C, Olivares K, Aguilera X, Ramírez-Santana M. Hormazábal J, et al. Vaccine X. 2023 Aug 26;15:100372. doi: 10.1016/j.jvacx.2023.100372. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37693843 Free PMC article.

188

Disease severity of COVID-19 in different phases of the pandemic: Do healthcare workers have better outcomes?

Yang X, Shi F, Zhang J, Gao H, Chen S, Olatosi B, Weissman S, Li X. Yang X, et al. Vaccine X. 2023 Aug 26;15:100377. doi: 10.1016/j.jvacx.2023.100377. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37681205 Free PMC article.

189

COVID-19 vaccination preferences during a pause in Johnson & Johnson vaccine administration.

Wagner AL, Zhang F, Kerekes S, Shih SF, Zhao L. Wagner AL, et al. Vaccine X. 2023 Aug 18;15:100373. doi: 10.1016/j.jvacx.2023.100373. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37674932 Free PMC article.

190

Seroconversion of hepatitis B vaccine among patients from outpatient clinic in Georgia.

Kanchelashvili G, Kamkamidze G, Davitadze M, Bzishvili N, Abzianidze T, Gulbiani L, Butsashvili M. Kanchelashvili G, et al. Vaccine X. 2023 Aug 22;15:100375. doi: 10.1016/j.jvacx.2023.100375. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37663048 Free PMC article.

191

Vaccine traceability: Key learnings from the supply chain initiative by manufacturers from emerging countries.

Pagliusi S, Madrid Y, Bramanti Y, Wilmansyah T, Yu H, Acebal A, Krishnamurthy KR, Raju Pinnamaraju V, Jadhav P, Park R, Yang L. Pagliusi S, et al. Vaccine X. 2023 Aug 4;15:100366. doi: 10.1016/j.jvacx.2023.100366. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37663047 Free PMC article.

192

Low uptake of COVID-19 vaccines in Wad Medani City, Gezira State, Sudan: Hesitancy and poor accessibility.

Elmustafa M, Wedaa A, Babiker H, Elmajzoup A, Ali H, Ahmed R. Elmustafa M, et al. Vaccine X. 2023 Aug 13;15:100369. doi: 10.1016/j.jvacx.2023.100369. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37649618 Free PMC article.

193

Persistence of antibody responses to COVID-19 vaccines among participants in the COVID-19 Community Research Partnership.

Berry AA, Tjaden AH, Renteria J, Friedman-Klabanoff D, Hinkelman AN, Gibbs MA, Ahmed A, Runyon MS, Schieffelin J, Santos RP, Oberhelman R, Bott M, Correa A, Edelstein SL, Uschner D, Wierzba TF; COVID-19 Community Research Partnership. Berry AA, et al. Vaccine X. 2023 Aug 11;15:100371. doi: 10.1016/j.jvacx.2023.100371. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37649617 Free PMC article.

194

Exploring Shigella vaccine priorities and preferences: Results from a mixed-methods study in low- and middle-income settings.

Fleming JA, Gurley N, Knudson S, Kabore L, Bawa JT, Dapaah P, Kumar S, Uranw S, Tran T, Mai LTP, Odero C, Obong'o C, Aburam K, Wanjiru S, Hanh NTM, Dung LP, Hausdorff WP. Fleming JA, et al. Vaccine X. 2023 Aug 9;15:100368. doi: 10.1016/j.jvacx.2023.100368. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37636544 Free PMC article.

195

Estimated health and economic impact of using high-dose influenza vaccine on respiratory and circulatory plus respiratory hospitalizations of older adults in Australia.

Raina MacIntyre C, Kevin Yin J, Felter C, Menzies RI, Thommes E, Largeron N, Moa AM, Trent M, Costantino V, Choi S, Alvarez FP. Raina MacIntyre C, et al. Vaccine X. 2023 Aug 4;15:100365. doi: 10.1016/j.jvacx.2023.100365. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37609557 Free PMC article.

196

Comparative estimates of crude coverage of the Mexican immunization program: Findings from a national survey.

Angélica LH, Carlos CS, Julia Berenice RG, Silvia MV, Ramon DA, Luis DA, Reyna Lizette PD. Angélica LH, et al. Vaccine X. 2023 Aug 3;15:100364. doi: 10.1016/j.jvacx.2023.100364. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37601323 Free PMC article.

197

Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance.

Nantanee R, Jaru-Ampornpan P, Chantasrisawad N, Himananto O, Papakhee S, Sophonphan J, Tawan M, Jupimai T, Anugulruengkitt S, Puthanakit T; Study Team. Nantanee R, et al. Vaccine X. 2023 Aug 5;15:100367. doi: 10.1016/j.jvacx.2023.100367. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37601322 Free PMC article.

198

Post-marketing safety surveillance of the rotavirus vaccine in India.

Kang G, Lakhkar A, Bhamare C, Dharmadhikari A, Narwadkar J, Kanujia A, Desai S, Gunale B, Poonawalla CS, Kulkarni PS. Kang G, et al. Vaccine X. 2023 Aug 1;15:100362. doi: 10.1016/j.jvacx.2023.100362. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37593522 Free PMC article.

199

COVID-19 vaccine eligibility of pregnant and lactating women in Bangladesh: Gap between policy and policy interpretation among policymakers and healthcare workers.

Limaye RJ, Fesshaye B, Singh P, Zavala E, Akter S, Siddiqua TJ, Rahman H, Ali H, Karron R. Limaye RJ, et al. Vaccine X. 2023 Aug 9;15:100370. doi: 10.1016/j.jvacx.2023.100370. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37589020 Free PMC article.

200

Evaluation of a novel liquid stabilised peste des petits ruminants vaccine: Safety and immunogenic efficacy in sheep and goats in the field in Jordan.

Crofts F, Al-Majali A, Gerring D, Gubbins S, Hicks H, Campbell D, Wilson S, Chesang L, Stuke K, Cordel C, Parida S, Batten C. Crofts F, et al. Vaccine X. 2023 Aug 4;15:100363. doi: 10.1016/j.jvacx.2023.100363. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37583870 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

512 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

512 results

Results by year